Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Matthew Risendal"'
Publikováno v:
Blood. 136:23-24
The standard of care for patients with newly diagnosed multiple myeloma who are transplant eligible is induction therapy followed by conditioning with high dose melphalan and autologous hematopoietic cell transplant (HCT). While the value of a single
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6e4c8165f83d768eb69c117bac2b79f
https://doi.org/10.1182/blood-2020-136800
https://doi.org/10.1182/blood-2020-136800
Publikováno v:
The Canadian journal of urology. 26(2)
The TNM staging system is used globally as the standard for interpreting the extent of cancer. Currently, T3a renal cell carcinoma is classified as tumor extending into the perinephric fat or renal vein. Prognostic outcomes may vary among renal cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::95d2e6116b533286adb36a4bd30c50a4
https://pubmed.ncbi.nlm.nih.gov/31012835
https://pubmed.ncbi.nlm.nih.gov/31012835
Autor:
Joan Bolling, Roy T. Sabo, Matthew Risendal, Amir A. Toor, William B. Clark, John M. McCarty, Priscilla Mpasi, Catherine H. Roberts, Harold M. Chung, Allison F. Hazlett
Publikováno v:
Blood. 120:3123-3123
Abstract 3123 Background: Multiple myeloma (MM) is a plasma cell malignancy with variable prognosis depending on disease features such as β2m level and cytogenetics. High dose therapy and stem cell transplantation (SCT) remains the current standard
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ffa01c2a2fa3eb5506ea4469716cebf
https://doi.org/10.1182/blood.v120.21.3123.3123
https://doi.org/10.1182/blood.v120.21.3123.3123
Feasibility of risk stratified allocation to single versus tandem autologous SCT in multiple myeloma
Autor:
John M. McCarty, Allison Hazlett, Roy T. Sabo, Matthew Risendal, Catherine H. Roberts, Priscilla Mpasi, Harold M. Chung, William B. Clark, Amir A. Toor, Joan Bolling
Publikováno v:
Journal of Clinical Oncology. 30:e18550-e18550
e18550 Background: Multiple myeloma (MM) is a plasma cell malignancy with variable prognosis depending on disease features such as β2m and cytogenetics. High dose therapy and stem cell transplantation (SCT) remains the current standard of care for M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4ffc11bb7bf185d488320e8f44f4c35
https://doi.org/10.1200/jco.2012.30.15_suppl.e18550
https://doi.org/10.1200/jco.2012.30.15_suppl.e18550